| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Tyra Biosciences, Inc. | Other* | Common Stock | 6.45M | $83.9M | $13.01 | Feb 6, 2024 | Direct |
| Tango Therapeutics, Inc. | Other* | Common Stock | 8.2M | $68.8M | $8.39 | Oct 16, 2023 | Direct |
| Tango Therapeutics, Inc. | Other* | Common Stock | 6.99M | $58.6M | $8.39 | Oct 13, 2023 | Indirect |
| iTeos Therapeutics, Inc. | Other* | Common Stock | 2.95M | $51.6M | $17.50 | May 10, 2024 | Direct |
| Tango Therapeutics, Inc. | Other* | Prefunded Warrant | 2.34M | $12.1M | $5.15 | Aug 11, 2023 | Direct |
| Tyra Biosciences, Inc. | Other* | Warrant (right to purchase) | 705K | $9.17M | $13.01 | Feb 6, 2024 | Direct |
| Odonate Therapeutics, Inc. | 10%+ Owner | Common Stock | 4.21M | $6.6M | $1.57 | Nov 24, 2021 | Direct |
| Rain Oncology Inc. | Aaron Davis, the CEO of Boxer Capital, LLC, is a director of Rain Oncology Inc. | Common Stock | 1.15M | $1.39M | $1.21 | May 22, 2023 | Direct |
| Tyra Biosciences, Inc. | Other* | Common Stock | 85.9K | $1.12M | $13.01 | Feb 6, 2024 | Indirect |
| Mirati Therapeutics, Inc. | Other* | Common Stock | 0 | $59.02 | Jan 23, 2024 | Direct | |
| Mirati Therapeutics, Inc. | Other* | Common Stock | 0 | $59.02 | Jan 23, 2024 | Indirect | |
| Mirati Therapeutics, Inc. | Other* | Warrant (right to purchase) | 0 | Jan 23, 2024 | Direct | ||
| Mirati Therapeutics, Inc. | Other* | Warrant (right to purchase) | 0 | Jan 23, 2024 | Indirect |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| ITOS | iTeos Therapeutics, Inc. | May 10, 2024 | 1 | $20M | 4 | May 14, 2024 | Other* |
| TYRA | Tyra Biosciences, Inc. | Feb 6, 2024 | 2 | $10M | 4 | Feb 8, 2024 | Other* |
| MRTX | Mirati Therapeutics, Inc. | Jan 23, 2024 | 8 | $0 | 4 | Jan 25, 2024 | Other* |
| TNGX | Tango Therapeutics, Inc. | Oct 13, 2023 | 2 | $8.72M | 4/A | Oct 17, 2023 | Other* |
| TNGX | Tango Therapeutics, Inc. | Oct 9, 2023 | 2 | -$2.24M | 4 | Oct 11, 2023 | Other* |
| ITOS | iTeos Therapeutics, Inc. | Aug 23, 2023 | 3 | -$5.69M | 4 | Aug 25, 2023 | Other* |
| TNGX | Tango Therapeutics, Inc. | Aug 11, 2023 | 2 | $14.5M | 4/A | Oct 11, 2023 | Director, Other* |
| MRTX | Mirati Therapeutics, Inc. | Aug 11, 2023 | 2 | $35M | 4 | Aug 15, 2023 | Other* |
| MRTX | Mirati Therapeutics, Inc. | Aug 11, 2023 | 2 | $35M | 4 | Aug 15, 2023 | Other* |
| RAIN | Rain Oncology Inc. | May 22, 2023 | 1 | -$1.24M | 4 | May 24, 2023 | Aaron Davis, the CEO of Boxer Capital, LLC, is a director of Rain Oncology Inc. |
| TNGX | Tango Therapeutics, Inc. | Oct 11, 2022 | 3 | $1.04M | 4 | Oct 13, 2022 | 10%+ Owner |
| TNGX | Tango Therapeutics, Inc. | Oct 4, 2022 | 4 | $714K | 4 | Oct 6, 2022 | 10%+ Owner |
| ITOS | iTeos Therapeutics, Inc. | Mar 17, 2022 | 1 | -$20.3M | 4 | Mar 18, 2022 | 10%+ Owner |
| ITOS | iTeos Therapeutics, Inc. | Jan 3, 2022 | 14 | -$32.6M | 4 | Jan 5, 2022 | Director, 10%+ Owner |
| TYRA | Tyra Biosciences, Inc. | Dec 17, 2021 | 1 | $1.64M | 4 | Dec 21, 2021 | 10%+ Owner |
| ODT | Odonate Therapeutics, Inc. | Nov 22, 2021 | 2 | -$623K | 4 | Nov 24, 2021 | 10%+ Owner |
| ODT | Odonate Therapeutics, Inc. | Nov 17, 2021 | 3 | -$2.06M | 4 | Nov 19, 2021 | Director, 10%+ Owner |
| TYRA | Tyra Biosciences, Inc. | Sep 17, 2021 | 7 | $10M | 4 | Sep 17, 2021 | 10%+ Owner |
| TYRA | Tyra Biosciences, Inc. | Sep 14, 2021 | 0 | $0 | 3 | Sep 14, 2021 | 10%+ Owner |
| TNGX | Tango Therapeutics, Inc. | Aug 10, 2021 | 0 | $0 | 3 | Aug 20, 2021 | 10%+ Owner |